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pathogenic variants in the PSEN1 gene are known to be the most common cause of early-onset 
Alzheimer’s disease but there are few data on the frequency and spectrum of PSEN1 variants in Korea. 
In this study, we investigated PSEN1 variants in a consecutive series of clinically suspicious early-onset 
familial AD (EOFAD) Korean patients and their clinical characteristics and imaging findings. From 
January 2007 to December 2013, EOFAD patients with very early onset AD (<50 yr), early onset AD 
(<60 yr) with two or more relatives with AD, and early onset AD (<60 yr) with one or more first-degree 
relatives with very early onset AD (<50 yr) were enrolled in this study. Sequence analysis of the PSEN1 
gene was performed by Sanger sequencing. Neuroimaging data and conventional brain MRIs and FDG-
pet and/or [11c] piB-pet scans were analyzed in patients with PSEN1 variants. Among the 28 patients 
with EOFAD, six (21.4%, 6/28) patients had pathogenic or likely pathogenic variants in the PSEN1 
gene. Two pathogenic variants were p.Glu120Lys and p.Ser170Phe and four likely pathogenic variants 
were p.Thr119Ile, p.Tyr159Cys, p.Leu282Pro, and p.Ala285Ser. Two patients had variants of unknown 
significance, p.Tyr389His and p.Tyr389Ser. EOFAD patients with PSEN1 variants showed early AD 
onset, frequent visuospatial dysfunction, movement disorders, and rapid disease progression. Brain 
MRIs revealed diffuse cortical atrophy, including parietal lobe atrophy, and/or hippocampal atrophy. 
FDG-PET scans also revealed significant hypometabolism in the bilateral temporo-parietal regions. Our 
findings provide insight to better understand the genetic background of Korean EOFAD patients.
Alzheimer’s disease (AD, OMIM# 104300) is a progressive neurodegenerative disease characterized by memory 
loss and personality changes. AD is the most common type of dementia in the elderly, representing 50 to 70% of 
dementia cases1. AD can be classified into two subtypes, early-onset AD and late-onset AD, based on the age at 
onset2. A family history of AD is more frequent in early-onset AD (7%) than in late-onset AD (1.7%)3–5.
PSEN1 mutations are essential components of the γ-secretase complex and mutations in PSEN1 impair the 
γ-secretase cleavage system of amyloid precursor protein (APP) into beta amyloid (Aβ) fragments, resulting in 
an increased ratio of Aβ42 to Aβ406. Consequently, it can form insoluble toxic fibrils and lead to the aggregation of 
toxic Aβ deposited in extracellular amyloid plaques6,7.
It is important to characterize the preclinical stages of AD in the model of autosomal dominant Alzheimer’s 
disease with the expectation that future treatment may target the specific disease protein. The Dominantly 
Inherited Alzheimer Network (DIAN) was established for the purpose of identifying individuals at risk for auto-
somal dominant Alzheimer’s disease8. Its primary aim is to investigate the temporal ordering of AD pathophysio-
logical changes which occur in asymptomatic and symptomatic carriers and non-carriers of autosomal dominant 
Alzheimer’s disease mutations in genes such as PSEN1, PSEN2, and APP.
Therefore, in this study, we investigated the frequency and spectrum of PSEN1 variants in a consecutive series 
of clinically suspicious early-onset familial AD (EOFAD) Korean patients to determine the PSEN1 genetic back-
ground of EOFAD.
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Methods
Participants. Among 1,101 patients with AD who visited the Memory Disorder Clinic at Samsung Medical 
Center from January 2007 to December 2013, 149 patients were classified into the early-onset AD (EOAD) group 
(onset age < 60 years). Among them, we selected 28 clinically suspicious early-onset familial AD (EOFAD) 
patients using the following criteria: 1) very early disease onset (<50 years old), 2) early disease onset (<60 years 
old) with two or more affected relatives, and 3) early disease onset (<60 years old) with one or more affected 
first-degree relatives with early onset dementia (<60 years old). Age at onset was defined as the age at which the 
earliest episode of cognitive decline was reported.
All patients met the criteria for probable Alzheimer’s disease proposed by the National Institute of 
Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders 
Association (NINCDS-ADRDA)9 and also met the diagnosis of dementia due to Alzheimer’s disease10. At the 
initial visit, the patients were evaluated by a neurologist and underwent clinical interviews, a neurological exami-
nation, a battery of neuropsychological tests called the Seoul Neuropsychological Screening Battery (SNSB)11, and 
conventional brain MRI scans including T1 and T2 weighted imaging. Potential secondary causes of cognitive 
deficits were ruled out by laboratory tests, including complete blood counts, blood chemistry, vitamin B12 levels, 
folate levels, syphilis serology, and thyroid function tests. This study was approved by the Institutional Review 
Board of Samsung Medical Center. Informed consent was obtained from all subjects. All research was performed 
in accordance with relevant guidelines.
Genetic analysis. Genomic DNA (gDNA) was extracted from peripheral blood leukocytes using Wizard 
Genomic DNA Purification kits according to the manufacturer’s instructions (Promega, Madison, WI, USA). 
All exons and exon-intron boundaries of the PSEN1 gene were amplified by PCR using primers designed by the 
authors (available on request). PCR was performed with a thermal cycler model GeneAmp PCR system 9700 
(Applied Biosystems, Foster City, CA, USA). Sanger sequencing was performed with Big Dye Terminator Cycle 
Sequencing Ready Reaction kits (Applied Biosystems) on an ABI 3130xl Genetic Analyzer (Applied Biosystems). 
PSEN1 cDNA nucleotides were numbered according to the reference sequence GenBank accession number 
NM_000021.4. APOE genotyping was performed using TaqMan SNP Genotyping Assays (Applied Biosystems, 
Forster City, CA, USA) on a 7500 Fast Real-Time PCR System (Applied Biosystems) according to the manufactur-
er’s instructions. All variants were classified according to pathogenic criteria of the American College of Medical 
Genetics and Genomics and the Association for Molecular Pathology (ACMG-AMP) guidelines12. In addition, 
we compared the results of PSEN1 genetic analyses to 100 ethnically-matched normal control subjects from the 
Korean Genome Analysis Project (4845–301), the Korean Genome and Epidemiology Study (4851–302), and the 
Korean Biobank Project (4851–307, KBP-2014-031) supported by the Korean Center for Disease Control and 
Prevention, Republic of Korea. Four hundred exome data were also used as in-house controls. Additional analysis 
of PSEN2 and APP genes in the patients could not be performed because the samples were unavailable.
Results
Identification of PSEN1 variants. A total of 6 of the 28 patients carried pathogenic or likely pathogenic 
variants in the PSEN1 gene (21.4%, 6/28). Two pathogenic variants (PV), four likely pathogenic variants (LPV), 
and two variants of unknown significance (VUS) were identified. According to the age of onset, the PSEN1 var-
iants were found in four out of eight patients (50.0%) less than 50 years old at the age of onset and five out of 
18 patients (27.8%) less than 60 years old at the age of onset. Two pathogenic variants (p.Glu120Lys and p.Ser-
170Phe) were detected in Patients 1 and 2 with onset ages of 34 and 28, respectively. Four LPVs, p.Thr119Ile, 
p.Tyr159Cys, p.Leu282Pro, and p.Ala285Ser, were found in Patients 3, 4, 5, and 6 with onset ages of 58, 59, 40, 
and 54, respectively. The two VUSs were p.Tyr389His, and p.Tyr389Ser which involved the same amino acid 
residue. None of the patients with PSEN1 variants carried APOE ε4/ε4 alleles but one patient with LPV p.Tyr-
159Cys and two patients with VUSs had APOE ε3/ε4 alleles and one patient with PV p.Glu120Lys had APOE 
ε2/ε3 alleles. All VUSs were missense variants predicted to be damaging by PolyPhen-2 or SIFT and had GERP 
scores higher than 4 and CADD scores higher than 15, suggesting evolutionary conservation. The LPVs and the 
VUSs were not found in gnomAD (https://gnomad.broadinstitute.org/) or showed extremely low frequency in 
a non-neuro cohort (p. Tyr159Cys, 0.000005). In addition, all the LPVs and VUSs were not identified in 100 
ethnically-matched normal control subjects, or 400 in-house controls. Two VUSs were located on the seventh 
transmembrane domain of the PSEN1 gene (Table 1). Four LPVs and two VUSs occurred at amino acid residues 
which are highly conserved across species, including Homo sapiens and other mammals (Fig. 1).
Clinical and neuroimaging findings. Table 2 provides a summary of clinical and neuroimaging find-
ings for the eight patients with PSEN1 variants. The mean age of onset was 44.4 years (range, 28 to 59) and all 
patients had a family history of dementia (Fig. 2). Patient 1 with p.Glu120Lys showed memory impairment, 
visuospatial dysfunction, language impairment such as anomia, psychiatric symptoms, cerebellar ataxia, and par-
kinsonism. Patient 2 with p.Ser170Phe also showed memory impairment, biparietal dysfunction (visuospatial 
dysfunction and acalculia), and myoclonus. Patient 3 with p.Thr119Ile and Patient 5 with p.Leu282Pro presented 
depression and apathy as well as memory impairment and visuospatial dysfunction. Patient 4 with p.Tyr159Cys 
showed aphasia, anxiety, and parkinsonism. Patient 6 with p.Ala285Ser and Patient 7 with p.Tyr389His presented 
with left parietal symptoms (apraxia or acalculia) and Patient 8 with p.Tyr389Ser showed aphasia and biparietal 
dysfunction.
Brain MR images revealed diffuse cortical atrophy, including parietal lobe atrophy, and/or hippocampal atro-
phy. FDG-PET scans also displayed significant hypometabolism in the bilateral temporo-parietal regions. The 
four patients who had [11C] PiB-PET scans were all classified as PiB-positive (PiB+) using the measured global 
PiB uptake ratio values.
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Discussion
In this study, we investigated the frequency of PSEN1 gene variants in 28 clinically suspicious EOFAD patients 
selected from 1,101 AD patients in Korea. We identified eight variants in the PSEN1 gene, two PVs located at exon 
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(0.00) NA 4.53 26.8 NA NA
Table 1. Identified variants of the PSEN1 gene in 8 EOFAD patients. EOAD = Early onset Alzheimer’s 
disease; NA = not applicable; TM = transmembrane domain. *gnomAD, http://gnomad.broadinstitute.org/. 
†ALZFORUM Mutation Database, https://www.alzforum.org/mutations/psen-1.
Figure 1. Evolutionary conservation of the amino acid residues for LPV (blue) and VUS (red) sites. Multiple 
sequence alignment shows the amino acid sites of four LPVs and two VUSs, (A) c.356 C > T (p.Thr119Ile), 
c.358 G > A (p.Glu120Lys) and c.476 A > G (p.Tyr159Cys), (B) c.845 T > C (p.Leu282Pro), (C) c.853 G > T 
(p.Ala285Ser), (D) c.1165 T > C (p.Tyr389His) and c.1166 A > C (p.Tyr389Ser).
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(p.Leu282Pro p.Ala285Ser), and two VUSs located at exon 11 (p.Tyr389His, p.Tyr389Ser). Their phenotypes were 
consistent with those of previously reported cases and included early onset, frequent parietal symptoms, move-
ment disorders, and rapid progression. Our findings provide insight to better understand the genetic background 
in Korean EOFAD patients.
The strength of our study was that clinically suspicious EOFAD patients were chosen from a consecutively 
recruited large sample of patients who had standardized phenotyping for AD and underwent genetic test-
ing for PSEN1. Since PSEN1 gene analysis was not possible for all patients because of ethical problems and 
cost-effectiveness, we believe that our selection strategy was practical. However, we acknowledge some limita-
tions. First, we were unable to acquire DNA samples from other affected and unaffected family members either 
due to the absence of living affected relatives or the refusal for genetic analysis. Therefore, segregation analysis 
could not be performed. Second, we could not confirm AD pathology using brain autopsies. However, four cases 
among the eight PSEN1 confirmed patients had [11C] PiB-PET scans and were classified as PiB+ which were 
compatible with AD.
In the present study, PSEN1 gene variants were detected in eight AD patients. The frequency of PSEN1 gene 
variants in AD patients was 0.7% (8/1101) and might be reasonable considering that patients who are autosomal 
dominant inherited are less than 1% of all AD patients4,7. EOFAD with onset from 30 to 60 years of age accounts 
for 1 to 6% of all AD cases13. Approximately 60% of EOAD cases had multiple first-to-second degree affected 
relatives and 13% were inherited in an autosomal dominant manner14. Among EOFAD patients, mutations in 
PSEN1 genes have been reported in 55% (17/31) of the patients in the United Kingdom and 59% (20/39) in a 
French cohort14,15. However, the proportion of PSEN1 mutations was lower in Chinese (15.2%, 4/32) and Polish 
cohorts (17%, 7/41)16,17. In Korea, 1.9% (2/104) of the EOAD patients carried a PV or LPV in the PSEN1 gene18. 
The variable frequency of PSEN1 pathogenic variants might be due to differences in subject inclusion criteria, 
such as the age of onset, the number of family members, and the degree of relatives with AD.
In this study, we identified two PVs, p.Glu120Lys in Patient 1 and p.Ser170Phe in Patient 2. These two are the 
first PVs identified in Korean patients with AD. The p.Glu120Lys variant was detected in a Danish AD patient 
with spastic paraparesis who was 43 at the age of onset19 and a Jewish-Israeli family with early-onset Alzheimer 
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Table 2. Clinical and neuroimaging findings in the 8 EOFAD patients with PSEN1 gene variants. EOAD = Early 
onset Alzheimer’s disease; NA = not applicable; MMSE = Mini-mental State Examination.
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with early-onset or familial Alzheimer’s disease19,21,22. Our patient presented with memory impairment, anomia, 
depression, and apathy at 34 years old and also showed movement disorders, including cerebellar ataxia, par-
kinsonism, and dystonia. The p.Ser170Phe variant was originally described in an English family with EOFAD 
in which the onset of memory loss began at 26 to 27 years of age and the average duration of the disease was 
11 years before death23. Since then, two more cases were reported in Polish and Italian patients24,25. These two 
cases showed very early-onset AD before the third decade of life. Consistent with previous cases, our patient 
with the p.Ser170Phe (Patient 2) variant developed symptoms at 28 years of age and showed a very rapid disease 
progression.
Among four LPVs, three LPVs have been reported as different amino acid changes in the same codons as 
those causing familial AD: the tyrosine at codon 159, the leucine at codon 282, and the alanine at codon 285. 
Previously a missense variant affecting the tyrosine at codon 159 (p.Tyr159Phe) was reported in a 43-year-old 
female with familial AD26. In the current study, Patient 4 with the p.Tyr159Cys variant showed parkinsonism, as 
well as cognitive impairment, with age of onset at 59. Different amino acid changes in the leucine at codon 282 
in variants p.Leu282Phe, p.Leu282Arg, and p.Leu282Val have been repeatedly described as a cause of familial 
AD27–29. Similar clinical features were observed in patients with an amino acid alteration in the leucine at codon 
282, who had symptom onset in their forties, late myoclonus, and seizures30. Patient 5 carried the p.Leu282Pro 
variant and was 40 years old at the age of onset, however, this patient did not show myoclonus or seizures until 
three years after the onset of AD. There are three prior reports of variants (p.Ala285Val) affecting the alanine at 
codon 28531–33. The mean age at onset was 46.7 and the patients had a relatively indolent course (range, 8–19 
years) with progressive global cognitive impairment32,33. In the present study, Patient 6, carrying p.Ala285Ser, 
showed an insidious personality change, including delusion, depression, and anxiety, and progressive memory 
impairment, which was a similar clinical presentation as in the previous studies.
One LPV, the p.Thr119Ile variant in exon 5, was reported in EOAD patients34,35. Patient 3 who carried this var-
iant showed an age at onset of 50 years. Our patient began with prominent memory impairment and depression, 
followed by visuospatial dysfunction and global cognitive impairment without atypical features. There has been 
no prior report of a sequence variant affecting this region.
We identified a VUS of C to T and A at codon 389 in the PSEN1 gene which resulted in the substitution of 
tyrosine with histidine (p.Tyr389His) in Patient 7 and serine (p.Tyr389Ser) in Patient 8. Patient 7 had variant 
p.Tyr389His and showed memory impairment, apraxia, acalculia, and parkinsonism with an age of onset at 39 
Figure 2. Pedigrees of EOFAD patients with PSEN1 variants.
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years. Patient 8, carrying p.Tyr389Ser, showed memory impairment, aphasia, apraxia, acalculia, parkinsonism, 
and apathy with an age of onset at 50 years.
To date, approximately 200 different variants discovered in the PSEN1 gene have been associated with AD 
and the variants have revealed heterogeneity in clinical phenotypes36. EOFAD patients with PVs or LPVs in 
the PSEN1 gene predominantly showed memory, visuospatial, and language dysfunctions. Along with cogni-
tive impairments, atypical clinical features may be present in the course of the disease, such as behavioral and 
psychiatric features, parkinsonism, myoclonus, epileptic seizures, spastic paraparesis, aphasia, and cerebellar 
ataxia5,36–38. Clinical features of EOFAD seem to be different from those of sporadic AD, which are early onset, 
frequent parietal symptoms, movement disorders, and rapid progression.
In conclusion, we identified two PVs, four LPVs, and two VUSs in the PSEN1 gene in eight EOFAD patients. 
Although variants in the PSEN1 gene are a rare cause of AD, the identification of PSEN1 PVs will contribute 
to a better understanding of the genetic background in Korean EOFAD patients. Furthermore, these findings 
could apply not only to identification of novel targets for genetic testing but to development of preventative and 
curative therapies for AD. Further clinical, biochemical, and molecular studies are needed to establish better 
genotype-phenotype correlations between EOFAD symptoms and PSEN1 variants.
Data availability
The data that support the findings of this study are available on request from the corresponding author. The data 
are not publicly available due to privacy restrictions.
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